TP53 and cancer: In vitro experiments on various cancer cell lines and on primary B-CLL cells demonstrated that membrane-permeant inhibitors of Kv1.3 can kill cancer cells independently of p53 status [162,163,164], BCL-2 overexpression [164] and the presence of BAX and BAK [156].